Table I.
Baseline characteristics of the 114 multiple myeloma patients.
| Characteristics | Non-ASCT (n=72) | ASCT (n=42) |
|---|---|---|
| Age, years | ||
| Median (range) | 57 (29–65) | 53 (41–65) |
| Gender, male/female | 43/29 | 30/12 |
| M component, n (%) | ||
| IgG | 41 (57.0) | 25 (59.5) |
| IgA | 19 (26.4) | 6 (14.3) |
| IgD | 2 (2.7) | 5 (11.9) |
| Light chain | 10 (13.9) | 6 (14.3) |
| DS stage, n (%) | ||
| I | 0 | 0 |
| II | 15 (20.8) | 14 (33.3) |
| III | 57 (79.2) | 28 (66.7) |
| ISS stage, n (%) | ||
| I | 1 (1.4) | 1 (2.4) |
| II | 61 (84.7) | 32 (76.2) |
| III | 10 (13.9) | 9 (21.4) |
| Number of induction cycles, median (range) | 5 (2–10) | 4 (3–8) |
| Best response after induction therapy, n (%) | ||
| CR | 19 (26.4) | 13 (31.0) |
| VGPR | 22 (30.6) | 14 (33.3) |
| PR | 31 (43.0) | 15 (35.7) |
| Induction regimen, n (%) | ||
| Bortezomib | 55 (76.4) | 25 (59.5) |
| Thalidomide | 17 (23.6) | 17 (40.5) |
| Maintenance therapy, n (%) | ||
| Yes | 40 (55.6) | 25 (59.5) |
| No | 32 (44.4) | 17 (40.5) |
ASCT, autologous hematopoietic stem cell transplantation; DS, Durie-Salmon staging system; ISS, International Staging System; CR, complete response; PR, partial response; VGPR, very good PR.